Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | CD44 | P16070 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.34 |
| ▸ | HTR3B | O95264 | 2/20 | 0.34 |
| ▸ | HTR3A | P46098 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14256816 | 0.82 | HTR3E (0.50) | MAPK1TDP1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL8935677 | 0.78 | ALDH1A1 (0.44) | MAPK1TDP1TSHRALDH1A1TP53 | |
| SCHEMBL12116179 | 0.78 | MAPK1 (0.58) | MAPK1TDP1TSHRALDH1A1TP53 | |
| SCHEMBL30396176 | 0.78 | MAPK1 (0.58) | MAPK1TDP1TSHRALDH1A1TP53 | |
| SCHEMBL3922528 | 0.77 | TDP1 (0.68) | MCL1MAPK1TDP1GRIN2DGRIN3B | |
| SCHEMBL12216540 | 0.74 | TDP1 (0.43) | MAPK1TDP1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL1274930 | 0.74 | ALDH1A1 (0.38) | MAPK1TDP1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL29577280 | 0.74 | ALDH1A1 (0.38) | MAPK1TDP1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL11213752 | 0.74 | BRD4 (0.40) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL14382106 | 0.73 | MAPK1 (0.38) | MAPK1TDP1GRIN2DGRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828202-B1 | RAPAMCYIN ANALOGUES AND THE USES THEREOF IN THE TREATMENT OF NEUROLOGICAL, PROLIFERATIVE AND INFLAMMATORY DISORDERS | WYETH LLC (US) | 2012-03-14 | — | — | EP | claimed |
| CN-101084227-B | Rapamycin analogs and their use for treating neurological disorders, proliferative and inflammatory diseases | WYETH CORP | 2011-11-16 | — | — | CN | claimed |
| US-7560457-B2 | Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders | WYETH (US) | 2009-07-14 | — | — | US | claimed |
| CN-101084227-A | Rapamycin analogs and their use for treating neurological disorders, proliferative and inflammatory diseases | WYETH CORP (US) | 2007-12-05 | — | — | CN | claimed |
| US-7276498-B2 | Rapamycin analogues and uses thereof in the treatment of neurological disorders | WYETH (US) | 2007-10-02 | — | — | US | claimed |
| EP-1828202-A2 | RAPAMCYIN ANALOGUES AND THE USES THEREOF IN THE TREATMENT OF NEUROLOGIAL PROLIFERATIVE AND INFLAMMATORY DISORDERS | Wyeth a Corporation of the State of Delaware (US) | 2007-09-05 | — | — | EP | claimed |
| US-20070142423-A1 | Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders | WYETH (US) | 2007-06-21 | — | — | US | claimed |
| WO-2006068932-A2 | RAPAMYCIN ANALOGUES AND THE USES THEREOF IN THE TREATMENT OF NEUROLOGICAL, PROLIFERATIVE, AND INFLAMMATORY DISORDERS | WYETH (US) | 2006-06-29 | — | — | WO | claimed |
| US-20060135549-A1 | Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative,and inflammatory disorders | WYETH (US) | 2006-06-22 | — | — | US | claimed |
| EP-1891076-B1 | SUBSTITUTED TETRAHYDROQUINOLINES | MERCK PATENT GMBH (DE) | 2016-01-27 | — | — | EP | disclosed |
| EP-1828202-B1 | RAPAMCYIN ANALOGUES AND THE USES THEREOF IN THE TREATMENT OF NEUROLOGICAL, PROLIFERATIVE AND INFLAMMATORY DISORDERS | WYETH LLC (US) | 2012-03-14 | — | — | EP | disclosed |
| CN-101084227-B | Rapamycin analogs and their use for treating neurological disorders, proliferative and inflammatory diseases | WYETH CORP | 2011-11-16 | — | — | CN | disclosed |
| US-7795252-B2 | Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders | PFIZER INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100196355-A1 | Immunophilin Ligands and Methods for Modulating Immunophilin and Calcium Channel Activity | WYETH (US) | 2010-08-05 | — | — | US | disclosed |
| CN-101084227-A | Rapamycin analogs and their use for treating neurological disorders, proliferative and inflammatory diseases | WYETH CORP (US) | 2007-12-05 | — | — | CN | disclosed |
| US-7276498-B2 | Rapamycin analogues and uses thereof in the treatment of neurological disorders | WYETH (US) | 2007-10-02 | — | — | US | disclosed |
| EP-1828202-A2 | RAPAMCYIN ANALOGUES AND THE USES THEREOF IN THE TREATMENT OF NEUROLOGIAL PROLIFERATIVE AND INFLAMMATORY DISORDERS | Wyeth a Corporation of the State of Delaware (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20070142423-A1 | Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders | WYETH (US) | 2007-06-21 | — | — | US | disclosed |
| WO-2006068932-A2 | RAPAMYCIN ANALOGUES AND THE USES THEREOF IN THE TREATMENT OF NEUROLOGICAL, PROLIFERATIVE, AND INFLAMMATORY DISORDERS | WYETH (US) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135549-A1 | Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative,and inflammatory disorders | WYETH (US) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100196355-A1 | Immunophilin Ligands and Methods for Modulating Immunophilin and Calcium Channel Activity | CACNG4, CACNG7, CACNG2 | MCL1 2164/4885MAPK1 4351/4885TDP1 1605/4885 |
| US-20070142423-A1 | Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders | RPTOR, MTOR, RICTOR | MCL1 3315/4885MAPK1 526/4885TDP1 3332/4885 |
| US-20060135549-A1 | Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative,and inflammatory disorders | RPTOR, MTOR, RICTOR | MCL1 3315/4885MAPK1 526/4885TDP1 3332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.